Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITEIIIB) - Trial NCT06229665
Access comprehensive clinical trial information for NCT06229665 through Pure Global AI's free database. This Phase 2/3 trial is sponsored by LumiThera, Inc. and is currently Recruiting. The study focuses on Dry Age-related Macular Degeneration. Target enrollment is 75 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
LumiThera, Inc.
Timeline & Enrollment
Phase 2/3
Oct 25, 2023
Jun 01, 2025
Primary Outcome
Early Treatment Diabetic Retinopathy Study (ETDRS) Best-Corrected Visual Acuity (BCVA)
Summary
This study is an open-label, prospective, multi-center extension study on the continued use
 of photobiomodulation (PBM) in subjects with dry age-related macular degeneration (AMD) that
 participated in the CSP005 LIGHTSITE III study.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06229665
Device Trial